MMP9 and THBS2 |
matrix metallopeptidase 9 |
thrombospondin 2 |
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
- Signaling by PDGF
- Defective B3GALTL causes Peters-plus syndrome (PpS)
- O-glycosylation of TSR domain-containing proteins
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
|
MMP9 and CXCL6 |
matrix metallopeptidase 9 |
C-X-C motif chemokine ligand 6 |
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
|
MMP9 and TFPI |
matrix metallopeptidase 9 |
tissue factor pathway inhibitor |
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
- Extrinsic Pathway of Fibrin Clot Formation
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
- Coagulation factor VIIa Recombinant Human
- Dalteparin
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
|
MMP9 and PLG |
matrix metallopeptidase 9 |
plasminogen |
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
- Platelet degranulation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Signaling by PDGF
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Dissolution of Fibrin Clot
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
- Alteplase
- Urokinase
- Reteplase
- Anistreplase
- Tenecteplase
- Streptokinase
- Tranexamic Acid
- Aminocaproic Acid
- Bicine
- Desmoteplase
- Aprotinin
- Copper
- Gabexate
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
|
MMP9 and MMP10 |
matrix metallopeptidase 9 |
matrix metallopeptidase 10 |
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
- Marimastat
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
|
MST1R and PTPRR |
macrophage stimulating 1 receptor |
protein tyrosine phosphatase receptor type R |
|
|
|
|
|
|
MX1 and TRPC4 |
MX dynamin like GTPase 1 |
transient receptor potential cation channel subfamily C member 4 |
- ISG15 antiviral mechanism
- Interferon alpha/beta signaling
|
- TRP channels
- Role of second messengers in netrin-1 signaling
|
|
|
|
|
NFYB and DRAP1 |
nuclear transcription factor Y subunit beta |
DR1 associated protein 1 |
- PPARA activates gene expression
- Activation of gene expression by SREBF (SREBP)
- Activation of gene expression by SREBF (SREBP)
- ATF4 activates genes in response to endoplasmic reticulum stress
- ATF6 (ATF6-alpha) activates chaperone genes
- ATF6 (ATF6-alpha) activates chaperone genes
- FOXO-mediated transcription of cell death genes
|
- Signaling by NODAL
- Signaling by Activin
|
|
|
|
|
NOTCH1 and MAML2 |
notch receptor 1 |
mastermind like transcriptional coactivator 2 |
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Processing in Golgi
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- Activated NOTCH1 Transmits Signal to the Nucleus
- Activated NOTCH1 Transmits Signal to the Nucleus
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
- Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Constitutive Signaling by NOTCH1 HD Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Notch-HLH transcription pathway
- Defective LFNG causes SCDO3
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 intracellular domain regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Notch-HLH transcription pathway
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
|
|
- Bicuspid aortic valve
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
|
|
NOTCH2 and MAML2 |
notch receptor 2 |
mastermind like transcriptional coactivator 2 |
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Processing in Golgi
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- Notch-HLH transcription pathway
- Defective LFNG causes SCDO3
- NOTCH4 Intracellular Domain Regulates Transcription
|
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 intracellular domain regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Notch-HLH transcription pathway
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
|
|
- Alagille syndrome
- Type II diabetes mellitus
- Hajdu-Cheney syndrome
|
|
NOTCH3 and MAML2 |
notch receptor 3 |
mastermind like transcriptional coactivator 2 |
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Processing in Golgi
- Notch-HLH transcription pathway
- Defective LFNG causes SCDO3
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- Noncanonical activation of NOTCH3
|
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 intracellular domain regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Notch-HLH transcription pathway
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
|
|
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL)
|
|
NOTCH4 and MAML2 |
notch receptor 4 |
mastermind like transcriptional coactivator 2 |
- Pre-NOTCH Processing in the Endoplasmic Reticulum
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Processing in Golgi
- Pre-NOTCH Processing in Golgi
- Notch-HLH transcription pathway
- Defective LFNG causes SCDO3
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Negative regulation of NOTCH4 signaling
- Negative regulation of NOTCH4 signaling
|
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 intracellular domain regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Notch-HLH transcription pathway
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
|
|
|
|
NTRK1 and PTPRR |
neurotrophic receptor tyrosine kinase 1 |
protein tyrosine phosphatase receptor type R |
- PLC-gamma1 signalling
- Signalling to RAS
- ARMS-mediated activation
- ARMS-mediated activation
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- NGF-independant TRKA activation
- TRKA activation by NGF
- TRKA activation by NGF
- Signalling to p38 via RIT and RIN
- PI3K/AKT activation
- PI3K/AKT activation
- Signalling to STAT3
|
|
- Amitriptyline
- Imatinib
- Regorafenib
|
|
- Neuroblastoma
- Thyroid cancer
|
|
ROR1 and PTPRR |
receptor tyrosine kinase like orphan receptor 1 |
protein tyrosine phosphatase receptor type R |
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
|
|
|
|
|
|
ROR2 and PTPRR |
receptor tyrosine kinase like orphan receptor 2 |
protein tyrosine phosphatase receptor type R |
- PCP/CE pathway
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
|
|
|
|
- Brachydactyly, including: type A; type B; type D; type E
- Robinow syndrome
|
|
NUMA1 and NCOA6 |
nuclear mitotic apparatus protein 1 |
nuclear receptor coactivator 6 |
- Recruitment of NuMA to mitotic centrosomes
- Mitotic Prophase
|
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
|
|
|
|
|
NUMA1 and SMC1A |
nuclear mitotic apparatus protein 1 |
structural maintenance of chromosomes 1A |
- Recruitment of NuMA to mitotic centrosomes
- Mitotic Prophase
|
- Meiotic synapsis
- Separation of Sister Chromatids
- Establishment of Sister Chromatid Cohesion
- Cohesin Loading onto Chromatin
- Resolution of Sister Chromatid Cohesion
- SUMOylation of DNA damage response and repair proteins
- Estrogen-dependent gene expression
|
|
|
|
- Cornelia de Lange syndrome (CdLS)
|
NUMA1 and TERF1 |
nuclear mitotic apparatus protein 1 |
telomeric repeat binding factor 1 |
- Recruitment of NuMA to mitotic centrosomes
- Mitotic Prophase
|
- Recognition and association of DNA glycosylase with site containing an affected pyrimidine
- Cleavage of the damaged pyrimidine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Cleavage of the damaged purine
- Cleavage of the damaged purine
- Meiotic synapsis
- Packaging Of Telomere Ends
- Telomere Extension By Telomerase
- DNA Damage/Telomere Stress Induced Senescence
|
|
|
|
|
NUMA1 and TERF2IP |
nuclear mitotic apparatus protein 1 |
TERF2 interacting protein |
- Recruitment of NuMA to mitotic centrosomes
- Mitotic Prophase
|
- Recognition and association of DNA glycosylase with site containing an affected pyrimidine
- Cleavage of the damaged pyrimidine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Cleavage of the damaged purine
- Cleavage of the damaged purine
- Meiotic synapsis
- Packaging Of Telomere Ends
- Telomere Extension By Telomerase
- DNA Damage/Telomere Stress Induced Senescence
|
|
|
|
|
NUMA1 and BRAP |
nuclear mitotic apparatus protein 1 |
BRCA1 associated protein |
- Recruitment of NuMA to mitotic centrosomes
- Mitotic Prophase
|
- RAF activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
|
|
|
|
|